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Background. The study was aimed to characterize tumor response after combined treatment employing electro-
chemotherapy with IL-12 gene electrotransfer in dogs with spontaneous mast cell tumors (MCT). 
Materials and methods. Eleven dogs with eleven MCTs were included in the study. Histological changes were in-
vestigated in biopsy specimens collected before the treatment (T0), and 4 (T1) and 8 weeks (T2) later. Cellular infiltrates 
were characterized immunohistochemically by using anti CD3, CD20, Foxp3 (Treg), CD68 and anti MHC-class II anti-
bodies. Proliferation and anti-apoptotic activity of neoplastic cells were assessed using anti Ki-67 and Bcl-2 antibodies. 
Angiogenetic processes were investigated immunohistochemically by using anti Factor VIII and anti CD31 antibodies 
and micro vessel density quantification.
Results. Histopathological examination of samples at T0 confirmed the diagnosis and the presence of scanty infil-
trates consisted mainly of T-lymphocytes and macrophages. At T1 and T2 neoplastic cells were drastically reduced 
in 7/11 cases, small clusters of neoplastic cells were detected in 3/11 cases and 1/11 cases neoplastic cells were still 
evident. Proliferation activity of neoplastic cells was significantly reduced at T1 and T2 and expression of anti-apoptotic 
protein at T1. Microvessel density was drastically reduced in all samples after treatment. The number of T-lymphocytes 
increased at T1, although not significant, while Treg were significant higher at T1 and macrophages at T2. 
Conclusions. The combined electrochemotherapy and IL-12 gene electrotransfer effectively induced a cellular 
response against neoplastic cells characterized mainly by the recruitment of T-lymphocytes and macrophages and 
a fibrotic proliferation with reduction of microvessels.
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Introduction
Electrochemotherapy is an ablative technique for 
the treatment of solid tumors of different histo-
types in human and veterinary oncology, with ap-
proximately 80% objective response of the treated 
tumors.1,2 It is based on electroporation as drug de-
livery method to tumors for the chemotherapeutic 
drugs bleomycin or cisplatin to improve the anti-
tumoral efficacy.1
Another biomedical application of electropora-
tion is plasmid DNA delivery to tumors (gene elec-
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trotransfer) for gene therapy. Preclinical and clini-
cal studies demonstrated effectiveness of different 
therapeutic plasmid DNA electrotransfer to tu-
mors as effective and safe method for local as well 
as loco-regional control of the cutaneous tumors.3 
The most studies explored gene electrotransfer of 
plasmid DNA coding for IL-12 cytokine.4-6 Its ef-
fectiveness was demonstrated also in treatment of 
spontaneous tumors in dogs.7-10 
A new treatment approach is combining local tu-
mor electrochemotherapy with gene therapy with 
plasmid coding for IL-12 peritumorally to skin.11 
Some preclinical data indicate that this approach 
provides in situ vaccination by electrochemother-
apy that is boosted by immunogene IL-12 peritu-
moral gene electrotransfer.3
Our previous report has provided evidence for 
this approach in MCT with excellent local tumor 
control and long lasting progression free survival 
of the treated dogs.11 To provide further evidence 
on the mechanisms of action, this study evaluates 
the histopatological features of those tumors in 
more detail to characterize whether this approach 
provides antitumor response also due to boosting 
the immune response. Therefore, we characterized 
tumor response including the cellular infiltrates 
at different time points post-electrochemotherapy 
with cisplatin combined with peritumoral IL-12 
electrotransfer in dogs, spontaneously affected by 
MCT and compared these results with those ob-
served in biopsies collected before the treatment. 
Proliferation and anti-apoptotic activity of neo-
plastic cells as well as the changes in microvessel 
density were also investigated, at the same timing.
Materials and methods
Animals and tumors
Between January and December 2010 eleven sub-
jects, 4 males and 7 females of different breeds 
ranging from 5 to 9 year-old (mean 6.5 years ± 
1.3 years) complied with inclusion criteria for the 
clinical survey (histologically confirmed MCT in 
different anatomical locations, good general health 
conditions with normal routine hematologic and 
biochemical profile without cardiac dysfunctions), 
were included in the study. The animals included 
in the study were those that owners refused any 
other type of standard treatment/surgery with 
wide excision of nodules.
Before the treatment a staging in all patients was 
performed according to modified WHO staging cri-
teria with physical examination, examination of tho-
racic radiographs, abdominal ultrasonography and 
basic bloodwork, consisting of a complete blood 
count with differential white cell count. Biochemical 
parameters (urea, creatinine, serum alkaline phos-
phatase and alanine aminotransferase) were deter-
mined using an automated chemical analyzer. 
The study was approved by the Ethical 
Committee of the Ministry of Agriculture, Forestry 
and Food of the Republic of Slovenia (approval 
No. 323-451/2004-9). Prior to the inclusion a writ-
ten consent for participation in the clinical study 
for each animal was obtained from their owners.
Electrochemotherapy and gene transfer
Electrochemotherapy and IL-12 gene electrotrans-
fer were performed as previously described.11 
Briefly, electrochemotherapy with intratumoral in-
jection of cisplatin (cis-diamminedichloroplatinum 
II, Cisplatyl; Aventis, Paris, France), at a concentra-
tion of 2 mg/ml in a dose of ~1 mg/cm3 was per-
formed just before electric pulses were delivered 
(8 pulses each of 100 μs duration and amplitude 
to electrode distance ratio of 1300 V/cm and fre-
quency of repetition 5 kHz with electric pulses 
generator Cliniporator™ (IGEA s.r.l., Carpi, Italy)). 
Two parallel stainless steel plate electrodes with 6 
mm distance between them or 4 needle row elec-
trodes with 4 mm distance according to the tumor 
size was used. Immediately after the electrochemo-
therapy 2 mg of the IL-12 plasmid was injected in-
tradermally in equidistant locations around tumor 
nodule in two locations.10 One high voltage pulse 
(amplitude to electrode distance ratio 1200 V/cm, 
duration 100 μs) and one low voltage pulse (ampli-
tude to electrode distance ratio 140 V/cm, duration 
400 μs)12 were delivered immediately after plasmid 
injection, using the same electric pulse generator 
and electrodes as mentioned above. 
Tissue sampling and processing
All the subjects were submitted to biopsy before 
(T0) the combined therapy and at 4 (T1) and 8 weeks 
(T2) post-treatment. Biopsies were fixed into 10% 
neutral buffered formalin and then processed rou-
tinely for paraffin embedding. Five-micrometers 
serial sections from all specimens were stained for 
haematoxylin and eosin (HE), Gomori’s modified 
trichrome stain and also mounted on treated glass 
slides (Superfrost Plus; Menzel-Glaser, Germany) 
for immunohistochemistry. Mast cell tumors were 
classified according to the Kiupel et al. (2011) clas-
sification.13
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Immunohistochemistry
Sections were dewaxed in xylene and rehydrat-
ed through graded alcohols prior to quenching 
endogenous peroxidase activity with 3% H2O2 
in distilled water for 20 minutes. Heat induced 
epitope retrieval with citrate buffer pH 6 was per-
formed. Immunohistochemical labelling was per-
formed manually with the Sequenza slide rack 
and cover-plate system (Shandon, Runcorn, UK). 
Non-specific antigen binding was blocked by in-
cubation with UltraVision Protein Block (TA-125-
PBQ; Thermo Scientific, Cheshire, UK). A panel 
of primary antibodies was applied to serial sec-
tions and incubated overnight at 4°C (Table 1). 
Antibody binding was detected by the Biotinylated 
Goat Polyvalent Secondary (TP-125-BN; Thermo 
Scientific, Cheshire, UK), Streptavidin Peroxidase 
(TS-125-HR; Thermo Scientific, Cheshire, UK) and 
DAB chromogen (SK-4105; ImmPact DAB, Vector, 
Burlingame, CA) as indicated by manufacturer’s 
instructions and slides were counterstained with 
haematoxylin. Substitution of the primary anti-
body with unrelated matched primary antibody 
was used to provide a negative control. Serial sec-
tions of canine lymph node were used as positive 
control. 
Slides were examined by two pathologists (C.S. 
and A.P.) without knowledge of the corresponding 
clinical and pathological data.
Quantification of immunolabeling
Bright field images were acquired at x20 magnifica-
tion with a Leica Microsystem DFC490 digital cam-
era mounted on Leica DMR microscope (Wetzlar, 
Germany). Counting were performed using a 
semiautomatic analysis system (LASV 4.3, Leica). 
Six 10,000 μm2 random fields of the central and pe-
riphery parts of the biopsies were used for count-
ing the number of infiltrating CD3+, CD20+, Foxp3+ 
(Treg+), CD68+ and MHC Class II+ cells and Bcl-
2+ and Ki-67+ neoplastic cells. Microvessel density 
was determined with Factor VIII and CD31 immu-
nostained section in six 50,000 μm2 random fields. 
Statistical analysis
Statistical analysis was performed using the statis-
tical package SPSS Advanced Statistics 21.0 (SPSS 
Inc., Chicago, IL, USA). ANOVA test was used to 
compare the composition of cell infiltrates and mi-
crovessel density at the different times of observa-
tion and post hoc analysis was made by Bonferroni 
Test. Statistical significance was based on a 5% 
(0.05) significance level.
Results 
Histologic features
At T0, all eleven skin tumors of different volumes 
(ranged from 0.2 to 16.9 cm3) were diagnosed as 
low grade MCTs and were characterized by sheets 
of polygonal neoplastic cells with abundant cyto-
plasm containing variable number of metachro-
matic granules, associated with moderate to mas-
sive infiltration of eosinophils, in the superficial 
and deep dermis, sometimes extending also to 
deep muscular layer (Figure 1A). Mitotic index 
was low (1 to 2 mitoses/10 HPF). Scanty multinu-
cleated cells were observed. Rarely necrotic areas 
TABLE 1. Antibodies used in the study
Antibody Specificity Type Species Source Dilution Pretreatment
Anti-human CD3 Pan-T lymphocytes Policonal Rabbit (A0552) Dako UK Ltd. Ely UK 1:50
Citrate buffer 
pH6
Anti-human CD20 Pan-B lymphocytes Policonal Rabbit (RB-9013-PO) Thermo Scientific, Chesire, UK 1:400 None
Anti-human Foxp3 T-reg lymphocytes Monoclonal Mouse (7979) Affymetrix eBioscience, san Diego, CA USA 1:100 Triss-EDTA pH9
Anti-human CD68 Macrophages Monoclonal Mouse (PG-M1) Thermo Scientific, Chesire, UK 1:100 Proteinase K
Anti-human Ki-67 Proliferating cells Monoclonal Mouse (MIB1; M7240) Dako UK Ltd. Ely UK 1:100
Citrate buffer 
pH6
Anti-human Bcl-2
Anti-
apoptotic 
protein
Monoclonal Mouse (610538) BD Biosciences, Wyckoff, NJ, USA5 1:100 Citrate buffer pH6
Anti-human Von 
Willebrand Factor -
Endothelial 
cells Policlonal Rabbit (A0082) Dako UK Ltd. Ely UK 1:300
Citrate buffer 
pH6
Anti-human CD31 Endothelial cells Monoclonal Mouse (JC70A) Dako UK Ltd. Ely UK 1:100
Citrate buffer 
pH6
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were present. Neoplastic cells were associated with 
reactive proliferation of connective tissue.
At T1 in biopsies collected from seven dogs 
with complete response, the neoplastic tissue was 
substituted by a fibrotic tissue composed by hori-
zontally oriented wavy collagen fibers associated 
with inflammatory infiltrates mainly constituted 
by lymphocytes and macrophages (Figure 1B). In 
three cases (partial response), single or small clus-
ters of neoplastic cells were still evident scattered 
among the fibrotic connective tissue, while in one 
dog neoplastic mast cells were still evident with 
features similar to T0.
At T2 biopsies collected from the seven dogs 
which did not present tumor cells at T1 were still 
free of neoplastic cells and consisted of a dense fi-
brous tissue still infiltrated by mononuclear cells. 
In other three cases (one with stable disease and 
two with partial response), thin aggregates of neo-
plastic mast cells between connective tissue bun-
dles, were still evident (Figure 1C), while in one 
case with partial response, neoplastic cells were 
numerous as at T0 and T1.
Immunohistochemistry 
Immunohistochemical analysis of biopsies col-
lected before the treatment and at different times 
of post-treatment revealed, in dermal infiltrates 
the presence of CD3+ T lymphocytes (Figure 2A, 
B), CD20+ B lymphocytes, Treg Lymphocytes 
(Figure 2C, D), and macrophages (Figure 2E, F), 
in different percentages, with T lymphocytes and 
macrophages representing the predominant cell 
populations. Results of immunohistochemical 
evaluation of inflammatory infiltrates at T0 and at 
T1 and T2 intervals are presented in the Figure 3. 
Overall, the T lymphocyte number increased at T1, 
even this difference was not statistically significant 
and was reduced at T2. Specifically, in biopsies col-
lected from subjects with complete remission, the 
number of CD3+ lymphocytes was significantly 
higher than from dogs with stable or progressive 
disease both at both T1 (8.1 ± 8.2 CD3+cells/ 10,000 
mm2  vs 3.4 ± 1.9 CD3+cells/ 10,000 mm2; p = 0.008) 
both at T2 (6.6 ± 4.4 CD3+cells/ 10,000 mm2 vs 3.2 ± 
1.9 CD3+cells/ 10,000 mm2; p = 0.001). Macrophages 
significantly increased at T2 (P = 0.006) and Treg 
lymphocytes significantly increased at T1 (p = 
0.0001), but no differences were observed at T2. No 
differences were observed in the presence of CD20 
lymphocytes at T1 and T2.
Immunohistochemical studies allowed to deter-
mine also the presence of proliferative and anti-ap-
optotic activities of neoplastic cells (Figure 4A, B; 
and C, D, respectively) as well as the micro-vessel 
density (Figure 4E, F) at T0, T1 and T2. Results were 
summarized in the Figure 5.
Proliferation activity of neoplastic cells was 
statistically reduced at T1 (p = 0.0001) and T2 (p = 
0.0001), while the number of neoplastic cells ex-
FIGURE 1. Histology of tissue samples collected before the combined 
therapy (T0) and at 4 (T1) and 8 weeks (T2) post-treatment. (A) At T0 
sheets of neoplastic cells with abundant cytoplasm containing variable 
number of metachromatic granules were present in the superficial and 
deep dermis; (B) At T1 The neoplastic tissue was substituted by a fibrotic 
tissue associated with scanty inflammatory infiltrates mainly constituted 
by mononuclear cells; (C) At T2 in dogs with partial response between 
connective tissue bundles were evident thin aggregates of neoplastic 
mast cells. Haematoxylin Eosin; bar = 100 mm.
A
B
C
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pressing the Bcl-2 anti-apoptotic protein was in-
creased at T1 (p = 0.0001), while was reduced 4 
weeks later. Proliferation activity of neoplastic 
cells in the biopsies collected from subjects with 
complete response was significantly lower than 
in the biopsies collected from dogs with stable or 
progressive disease both at T1 (1.5 ± 2.1 Ki-67+cells/ 
10,000 mm2  vs 2.5 ± 0.7 Ki-67+cells/ 10,000 mm2; p = 
0.012) both at T2 (0.4 ± 0.6 Ki-67+cells/ 10,000 mm2 
vs 2.2 ± 1.0 Ki-67+cells/ 10,000 mm2; p = 0.0001), as 
well as the expression of anti-apoptotic Bcl-2 pro-
tein both at both T1 (1.9 ± 2.0 Bcl-2+cells/ 10,000 
mm2  vs 3.2 ± 0.9 Bcl-2+cells/ 10,000 mm2; p = 0.004) 
both at T2 (1.4 ± 1.5 Ki-67+cells/ 10,000 mm2  vs 2.8 ± 
1.2 Ki-67+cells/ 10,000 mm2; p = 0.0001).
Microvessel density, determined using both an-
ti-Factor VIII and anti-CD31 antibodies, was drasti-
cally reduced at T1 (p = 0.000) and T2 (p = 0.0001), 
when compared with the samples collected before 
the treatment.
FIGURE 2. Immunoistochemical staining of tissue samples collected at T0 (A, C and E) and , T1 (B, D and E). CD3+ lymphocytes 
infiltrating the neoplastic tissue at T0 (A) and the fibrotic tissue at T1 (B). Scanty Foxp3+ Treg lymphocytes at the periphery of 
neoplastic tissue at T0 (C) and in a tissue sample collected at T1 (D). CD68+ macrophages in the neoplastic tissue at T0 (E) and in 
the fibrotic tissue at T1 (F). Immunohistochemical staining using DAB chromogen and haematoxylin counterstain. Bar = 100 mm.
A B
C D
E F
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Discussion
Histopathological evaluation of tissue biopsies af-
ter electrochemotherapy with cisplatin combined 
with peritumoral IL-12 gene electrotransfer dem-
onstrates that in the tumors with complete clinical 
response, pronouncedly reduced number and pro-
liferation rate of the tumor cells was obtained with 
significantly enhanced immune and anti-vascular 
response, which confirm our previously reported 
clinical results.11
At the best of our knowledge this is the first clin-
ical study that describes the histopathological and 
cellular changes induced in vivo by electrochemo-
therapy and peritumoral IL-12 electrotransfer in 
dogs bearing MCT, performed with the consent of 
the owners. The number of biopsies was reduced 
and made at distance from treatment with the aim 
to verify its effectiveness.
Already at four weeks post-treatment, in dogs 
with a complete responses histopathologic exami-
nation revealed a marked reduction of neoplastic 
cells, confirming the anticancer efficacy of the com-
bined electrochemotherapy and gene therapy. This 
reduction was even more evident four weeks later. 
On the contrary, in dogs with a partial response 
the reduction of neoplastic cell was lower at four 
weeks after treatment and this reduction was ab-
sent in dog with stable disease.
The reduced presence of neoplastic cells detect-
ed in the tissue samples from dogs with complete 
response was also associated with a reduced pro-
liferative activity of remnant neoplastic mast cells, 
characterized by a significant reduction of positiv-
ity to Ki-67 antibody and by a significant reduced 
expression of the anti-apoptotic Bcl-2 protein. The 
major mechanism of cisplatin tumor destruction 
consists of the formation of intrastrand and inter-
strand DNA adducts leading to DNA fragmenta-
tion that can ultimately lead to an apoptotic medi-
ate cell death as demonstrated in vitro and in vivo 
in murine models14 and the decreased expression 
of anti-apoptotic factor as the Bcl-2 protein pro-
motes higher death rate of the cancer cells.15
The time interval of 4 weeks of the first post-
treatment biopsy did not allow evaluation of the 
tumor necrosis, since at this time point dense fi-
brotic connective tissue with progressive reduction 
of microvessel density was already present. In ex-
perimental animal models has been demonstrated 
that electroporation induces a higher internaliza-
tion of cisplatin molecules with a rapid necrosis of 
neoplastic cells16 and vascular disrupting action by 
causing a rapid shutdown of tumour blood flow 
leading to reduced tumour oxygenation, increased 
tumour hypoxia and tumour necrosis.17
In this study, electrochemotherapy was associ-
ated with IL-12 gene electrotransfer with proven 
good local and locoregional antitumor effects.11 The 
potential for inducing an antitumoral immune re-
sponse to treat neoplastic disorders is well known, 
but the application of this technology has not yet 
been meaningfully transferred to the clinic. Local 
administration of recombinant cytokines directly 
into the tumor has proven to be much safer than 
systemic delivery.13 IL-12 is a natural occurring 
cytokine that showed potential success for treat-
ing cancer by inducing a specific anti-tumoral im-
mune response.18 Gene therapy with IL-12 pDNA 
showed to be effective to treat multiple tumor his-
totype in rodent models and induce an anti-tumor-
al immune response capable of affecting neoplastic 
tissues.14-16 Likewise, IL-12 gene therapy in canine 
species can induce tumor regression in spontane-
ous neoplasms of different histotypes.17,19,20
Another therapeutic approach that is currently 
extensively explored is combination of the abla-
tive techniques with different immunomodula-
tory approaches, either with immune checkpoint 
inhibitors, Treg depletion or immunostimulation.3 
In this context ablative techniques are considered 
as in situ vaccination with further boosting of the 
immune responsiveness of the organism. For this 
purpose, we postulated that electrochemotherapy 
FIGURE 3. Histogram of number of immune cells in 10,000 μm2 of tissue samples 
collected al T0, T1 and T2. Slight increase of CD3+ lymphocytes at T1, while 
macrophages significantly increased at T2 and Treg lymphocytes at T1. 
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could be in situ vaccination, which can be boost-
ed with peritumoral IL-12 gene electrotransfer, 
given peritumorally.3 Our clinical study on MCT 
supports this hypothesis, providing evidence that 
this treatment combination has excellent local tu-
mor control and also the long lasting disease free 
interval (between 3 and 4 years). Furthermore the 
present study immunohistologically supports the 
value of peritumoral IL-12 gene electrotransfer in 
boosting immune response of the organism, pro-
viding evidence of the presence of immune cells 
(T-lymphocytes and macrophages) in the tumors 
treated with electrochemotherapy and peritumor-
al IL-12 gene electrotransfer compared to tumors 
before therapy. There is also another study on 
sarcoids in horses, using the same combined treat-
ment in which increased number of CD4 and CD8 
lymphocytes sub-population confirmed induction 
of local immune response in treated tumors.21
Even though in our study the number of exam-
ined biopsies was limited, at 4 weeks post-treat-
ment our immunohistochemical results unequivo-
A B
C D
E F
FIGURE 4. Immunoistochemical staining of tissue samples collected at T0 (A, C and E) and , T1 (B, D and E). Ki-67+ neoplastic cells 
at T0 (A) and at T1 in a dog with partial response (B). Bcl-2+ neoplastic cells at T0 (C) and at T1 in a dog with partial response (D). 
Microvessels stained using an anti-CD31 primary antibody at T0 (E) and in the fibrotic tissue at T1 in a dog with a complete response 
(F). Immunohistochemical staining using DAB chromogen and haematoxylin counterstain. Bar = 100 mm.
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cally demonstrated an increase of T-lymphocytes 
in cellular infiltrates, higher in subjects with a 
complete response. T cells are the essential compo-
nents of the adaptive immune response and they 
interact closely with antigen presenting cells to 
release various cytokines that characterize the spe-
cific immune response also to neoplastic cells. The 
T-lymphocyte increase detected after four weeks 
post treatment was not evident 4 weeks later, in-
dicating that probably the anti-tumoral immune 
response induced by IL-12 is only transient as pre-
viously hypothesized or that due to the complete 
tumor regression, they could not be observed in 
higher numbers in the biopsies.15
The presence of B cells in examined subjects was 
not affected by IL-12 gene electrotransfer 4 as well 
as 8 weeks after the treatment. On the contrary, 
macrophages increased 8 weeks post-treatment, 
which was not related with the response to the ther-
apy. The macrophages, as any innate immune cells, 
act when tissue homeostasis is perturbed, releasing 
soluble mediators such as cytokines, chemokines, 
matrix remodeling proteases and reactive oxygen 
species and contribute to the maintenance of the 
inflammation and this late increase of these cells 
detected in treated subjects should be related with 
the tissue damage induced by the therapy. 
Tregs play an important role in down regu-
lating immune responses and an imbalance be-
tween numbers of Tregs and CD4+ and CD8+ 
T-lymphocytes contributes to the outcomes in 
cancer and infectious diseases. Many studies have 
demonstrated the in vivo role of these cells in the 
suppression of the immune response to the cancer 
in human22,23 and veterinary oncology.24,25 While 
Treg are immunosuppressive at sites of inflamma-
tion, the increase detected in our study should be 
explained by previous studies demonstrating that 
the adjuvant activity of IL-12 is short-lived due to 
regulatory Treg re-infintration. In fact, quantitative 
analysis of Treg kinetics in IL-12 treated tumors re-
vealed a transient loss of these cells followed by a 
rapid fold expansion of tumor Treg between days 3 
and 10 post treatment.26 So the increase of Treg ob-
served in our study should be related with the tim-
ing of tissue sampling after the treatment or due to 
the presence of inflammation.
In conclusion, our study confirmed the syner-
gic power of electrochemotherapy and IL-12 gene 
electrotransfer in canine species at immunohisto-
pathological level. It led to number of complete 
responses and extends survival through the induc-
tion of interferon gamma, inhibiting angiogenesis 
and increasing cytotoxic activity.3 
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